Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat.

MLA

Pan, Cassie, et al. “Neutrophil to Lymphocyte Ratio and Peripheral Blood Biomarkers Correlate with Survival Outcomes but Not Response among Head and Neck and Salivary Cancer Treated with Pembrolizumab and Vorinostat.” Head & Neck, vol. 45, no. 2, Feb. 2023, pp. 391–97. EBSCOhost, https://doi.org/10.1002/hed.27252.

APA

Pan, C., Wu, Q. V., Voutsinas, J., Houlton, J. J., Barber, B., Futran, N., Laramore, G. E., Liao, J. J., Parvathaneni, U., Martins, R. G., Fromm, J. R., & Rodriguez, C. P. (2023). Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat. Head & Neck, 45(2), 391–397. https://doi.org/10.1002/hed.27252

Chicago

Pan, Cassie, Qian Vicky Wu, Jenna Voutsinas, Jeffrey J Houlton, Brittany Barber, Neal Futran, George E Laramore, et al. 2023. “Neutrophil to Lymphocyte Ratio and Peripheral Blood Biomarkers Correlate with Survival Outcomes but Not Response among Head and Neck and Salivary Cancer Treated with Pembrolizumab and Vorinostat.” Head & Neck 45 (2): 391–97. doi:10.1002/hed.27252.